Open Access Research

Identification of stromal proteins overexpressed in nodular sclerosis Hodgkin lymphoma

Philippe Kischel1, David Waltregny1, Yannick Greffe1, Gabriel Mazzucchelli2, Edwin De Pauw2, Laurence de Leval3 and Vincent Castronovo1*

Author Affiliations

1 Metastasis Research Laboratory, GIGA Cancer, University of Liege, Bat. B23, CHU Sart Tilman Liège, B-4000 Liège, Belgium

2 Laboratory of Mass Spectrometry, Department of Chemistry, University of Liege, Bat. B6c, B-4000 Liège, Belgium

3 Department of Pathology, University Hospital of Liege, Bat. B23, CHU Sart Tilman Liège, B-4000 Liege, Belgium

For all author emails, please log on.

Proteome Science 2011, 9:63  doi:10.1186/1477-5956-9-63

Published: 5 October 2011

Abstract

Hodgkin lymphoma (HL) represents a category of lymphoid neoplasms with unique features, notably the usual scarcity of tumour cells in involved tissues. The most common subtype of classical HL, nodular sclerosis HL, characteristically comprises abundant fibrous tissue stroma. Little information is available about the protein composition of the stromal environment from HL. Moreover, the identification of valid protein targets, specifically and abundantly expressed in HL, would be of utmost importance for targeted therapies and imaging, yet the biomarkers must necessarily be accessible from the bloodstream. To characterize HL stroma and to identify potentially accessible proteins, we used a chemical proteomic approach, consisting in the labelling of accessible proteins and their subsequent purification and identification by mass spectrometry. We performed an analysis of potentially accessible proteins in lymph node biopsies from HL and reactive lymphoid tissues, and in total, more than 1400 proteins were identified in 7 samples. We have identified several extracellular matrix proteins overexpressed in HL, such as versican, fibulin-1, periostin, and other proteins such as S100-A8. These proteins were validated by immunohistochemistry on a larger series of biopsy samples, and bear the potential to become targets for antibody-based anti-cancer therapies.

Keywords:
Biomarker discovery; Lymphoma; Mass spectrometry; Tumour targeting